Appendix A — Key Comparative Evidence
| Dimension | C-DOT | Global benchmark | Implication |
| Financial capacity | ₹566.72 cr FY2025 income | Very large corporate revenue bases | Mission-based capital |
| Research/technology | ₹113.97 cr identifiable FY2025 spend* | Very large absolute R&D programmes | Scale and continuity |
| Human capital | About 1,000 professionals** | Tens of thousands | Talent scale/flexibility |
| IP | Established patent/IP base | Large global patent families | International IP strategy |
| Standards | Participation and Indian ecosystem role | Deep leadership | Move from participation to influence |
| Technology | Indigenous 4G/5G; growing 6G | Broad mature portfolios | Concentrate on strategic domains |
| Commercialisation | TOT, royalty, support income | Full product lifecycle/global sales | Professional productisation |
| Global reach | Primarily India-focused | Global footprints | Export pathways |
| Capital | Public funding + internal income | Private capital/capital markets/internal cash | External-capital mechanism |
| Autonomy | Public institutional framework | Corporate decision-making | Delegated operational powers |
* Not directly comparable to corporate R&D intensity.
** Current public workforce description; not audited FY2025 headcount.
Appendix B — Core C-DOT Financial Evidence
| Item | FY2024 | FY2025 |
| Total income | ₹406.68 cr | ₹566.72 cr |
| TOT/Royalty/TSR-FSR/Publications | ₹354.32 cr | ₹502.92 cr |
| Interest earned | ₹43.58 cr | ₹58.59 cr |
| Total expenditure | ₹775.32 cr | ₹820.82 cr |
| Establishment expenses | ₹396.43 cr | ₹479.96 cr |
| Operational expenses | ₹274.86 cr | ₹183.09 cr |
| Other administrative expenses | ₹58.70 cr | ₹101.41 cr |
| Depreciation | ₹45.33 cr | ₹56.36 cr |
| Excess expenditure | ₹368.64 cr | ₹254.09 cr |
| Total assets | ₹1,364.18 cr | ₹1,635.65 cr |
| Net block | ₹139.40 cr | ₹171.57 cr |
| Identifiable research/technology expenditure | ₹66.11 cr | ₹113.97 cr |
Appendix C — Methodological Limitations
- C-DOT total income is not equivalent to corporate revenue.
- C-DOT identifiable research/technology expenditure is reconstructed from schedule items and is not a directly disclosed corporate R&D measure.
- Samsung Electronics is diversified; its total R&D covers multiple technology businesses.
- Patent counts are not direct measures of technology quality; families, SEPs, licensing, citations and adoption should be considered separately.
- Standards leadership measures are heterogeneous across organisations.
- The international benchmark is institutional and ecosystem-oriented rather than a claim of identical mandates or ownership.
- The proposed institutional model is a research recommendation, not a statement of an existing Government decision.
Appendix D — Principal Source Base
- C-DOT Annual Report 2024–25.
- C-DOT Annual Report 2023–24.
- C-DOT International Benchmarking Preliminary Report, Stages 90–96.
- C-DOT Global Telecom Readiness Master Data Template.
- Huawei 2025 Annual Report and official R&D, patent and standards disclosures.
- Nokia 2025 annual/full-year reporting and official standards/6G disclosures.
- Ericsson Annual Report 2025 and official patents, standards and 6G disclosures.
- Samsung Electronics 2025 financial/business disclosures and official R&D, standards and 6G disclosures.